Evergreen Talk Series: Position paper published in JAPI indicated that Linagliptin is simplifying T2DM management in a Wide Range of Patients MDTV Bureau23 Jan 2024 11:30 AM ISTPresenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi, Dr Sameer I. Dani, an...
No need to discontinue SGLT2 inhibitors in response to initial eGFR decline in heart failure patients Medha Baranwal6 Jan 2024 11:00 AM ISTUSA: SGLT2 inhibitors should not be discontinued in response to an initial decline in the estimated glomerular filtration rate (eGFR) among patients...
Lupin bags tentative USFDA nod for Dapagliflozin and Saxagliptin Tablets Ruchika Sharma5 Jan 2024 11:11 AM ISTDapagliflozin and Saxagliptin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes...
Evergreen Talk Series: Clinical Considerations for Linagliptin and its combinations with Metformin, Dapagliflozin MD Brand Connect2 Jan 2024 11:00 AM ISTPresenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi, Dr Sameer I. Dani,...
Lupin Launches Dapaturn GM Range for Improved Approach to Manage Type 2 Diabetes MD Brand Connect1 Jan 2024 11:45 AM ISTGlobal pharma major Lupin Limited announced the launch of Dapaturn GM Forte for the treatment of diabetic patients in India. Lupin's Dapaturn GMâ„¢...
Dapagliflozin with semaglutide combo may help induce pharmacological remission of type 2 diabetes Jacinthlyn Sylvia29 Dec 2023 1:45 AM ISTA recent observational study unveiled positive outcomes regarding the combination therapy of a sodium-glucose co-transporter-2 inhibitor,...
Evergreen Talk Series: Linagliptin and Dapagliflozin combination for T2DM with Cardiovascular risk or established ASCVD MD Brand Connect21 Dec 2023 11:45 AM ISTPresenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi, Dr. Sameer I. Dani,...
Dapagliflozin may improve symptoms in patients with HFrEF with limited impact on exercise capacity Dr. Shravani Dali19 Dec 2023 7:45 PM ISTDapagliflozin may improve symptoms in patients with HFrEF with limited impact on exercise capacity suggests a new study published in the...
Linagliptin and Dapagliflozin: Therapeutic Applicability in T2DM with High CV Risk Dr. Kamal Kant Kohli13 Dec 2023 11:48 AM ISTType 2 Diabetes Mellitus and Cardiovascular DiseaseType 2 diabetes mellitus (T2DM) prevalence has been increasing globally, particularly in India (1)...
5mg Dapagliflozin every day attenuates CV events among diabetes patients with chronic HF Dr. Kamal Kant Kohli5 Dec 2023 11:15 AM ISTThe DAPPER study was conducted with the National Cardiovascular Center as the principal investigator, with 294 patients participating from 18...
First Indian Evidence: Triple FDC (DAPA, SITA, MET ER) Yields Better HbA1c Reduction in T2DM Patients Uncontrolled on Existing Therapy Dr. Kamal Kant Kohli2 Dec 2023 11:43 AM ISTAn approach of using a once-daily triple fixed-dose combination of dapagliflozin, sitagliptin, and metformin ER (extended-release) in Indian type 2...
Evergreen Talk Series: Clinical applicability of Linagliptin in T2DM across CKD spectrum and Dapagliflozin up to CKD stage 4 MD Brand Connect1 Dec 2023 11:17 AM IST Advertisement Presenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and...
